Key Considerations for Reshoring U.S. Drug Manufacturing
Nota Bene Episode 100: The New World Trade Order with Scott Maberry
Personal Jurisdiction: Not what you learned in law school [More with McGlinchey Ep. 4]
Foreign device manufacturers should anticipate greater chance of FDA inspection under new FDA leadership
For years, the U.S. International Trade Commission maintained that the potent remedies available under Section 337 were unavailable to intellectual property owners considered to be nothing more than “mere importers.” That...more
This Diagnosing Health Care episode dives into the key business operations and legal considerations for reshoring active pharmaceutical ingredient (or “API”) and finished drug product manufacturing to the United States. The...more